View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Clin. Ther. 2025;47:293–297 doi: 10.1016/j.clinthera.2025.01.005
Zhao et al. found that among patients with PsA or axSpA, JAKi were not associated with increased risk of CVD or common cancers compared to TNFi or IL-17i.
Arthritis Research & Therapy 2025;27:46 doi: 10.1186/s13075-025-03518-7
Haberman et al. analysed prescribing patterns and characteristics of PsA patients with
multi-b/tsDMARD failure, defined as requiring ≥4 b/tsDMARDs. Among 960 patients at the NYU Psoriatic Arthritis Centre, 17% met this criterion. These patients were more likely to be female, obese, and have higher rates of axial involvement and depression. They also exhibited greater disease activity, suggesting that both inflammatory and non-inflammatory factors contribute to multiple treatment failures.
J Am Acad Dermatol 2024;91:1150–7 doi: 10.1016/j.jaad.2024.07.1521
Lebwohl et al. investigated the efficacy and safety of risankizumab compared with placebo for treating palmoplantar psoriasis. At Wk16, significantly more patients receiving risankizumab achieved palmoplantar Investigator’s Global Assessment (ppIGA) 0/1 and PPASI75. The results were sustained through Wk52 with no new safety signals.
JAMA Dermatology 2025;161:56–66 doi: 10.1001/jamadermatol.2024.4688
Armstrong et al. evaluated the long-term safety and efficacy of deucravacitinib in patients with moderate to severe plaque psoriasis over a three-year period. The study found that exposure-adjusted incidence rates of AEs remained stable or declined over time, with no new safety signals emerging. Clinical response rates, including PASI75/90, were maintained, supporting the drug’s long-term efficacy.
J Rheumatol 2025. Epub ahead of print doi: 10.3899/jrheum.2024-0923
Gladman et al. assessed the impact of bimekizumab over 1 year on patient-reported symptoms, HRQoL, and work productivity in patients with PsA who were bDMARD-naïve or TNF-IR. The study showed that bimekizumab treatment resulted in sustained improvements across multiple domains, including pain, fatigue, physical function, and work impairment.
Arthritis & Rheumatology 2024. Epub ahead of print doi: 10.1002/art.43069
Poddubnyy et al. analysed five clinical trials to evaluate extra-musculoskeletal manifestations (EMMs) like uveitis, IBD, and psoriasis in patients treated with UPA. They observed low incidences across PsA, r-axSpA, and nr-axSpA. Numerically, uveitis rates were lower in
UPA-treated patients than in those receiving placebo, particularly in r-axSpA.
RMD Open. 2024 Dec 12;10(4):e004494. doi: 10.1136/rmdopen-2024-004494.
McInnes et al. assessed the efficacy of guselkumab over 48 weeks in patients with psoriatic arthritis who had an inadequate response to TNF inhibitors. The results demonstrated consistent improvements in joint, skin, and patient-reported outcomes across all baseline-defined subgroups. Guselkumab showed greater efficacy compared with placebo at Week 24, with responses maintained or improved through Week 48.
J Dermatol. 2024;51:1559–1571 doi: 10.1111/1346-8138.17448
Tsai et al. conducted a systematic literature review and network meta-analysis evaluating deucravacitinib and other systemic treatments for moderate-to-severe plaque psoriasis in Asian populations. The authors reported that deucravacitinib achieved PASI75 and PASI90 response rates of 66% and 40%, respectively, higher than placebo and apremilast.
Acta Derm Venereol. 2024 20;104:adv40737 doi: 10.2340/actadv.v104.40737
Renkhold et al. report that secukinumab significantly reduced psoriasis-associated pruritus intensity, improved skin lesions, and normalised histopathological changes, with stable neuroanatomy despite treatment discontinuation.
Rheumatology (Oxford). 2024:keae580 doi: 10.1093/rheumatology/keae580
Kavanaugh et al. conducted a post hoc analysis of a phase 2 trial examining deucravacitinib in patients with active psoriatic arthritis, focusing on the achievement of MDA components.
The analysis demonstrated that treatment with deucravacitinib led to a higher proportion of patients meeting each MDA component compared with placebo at 16 weeks.